COVID-19 drug works on Omicron: Drugmaker
Drugmaker GlaxoSmithKline says a lab analysis of the antibody-based COVID-19 therapy it is developing with US partner Vir has shown the drug is effective against the new Omicron variant.
In a statement, the British drugmaker says lab tests and a study on hamsters have demonstrated the sotrovimab antibody cocktail to work against viruses that were bio-engineered to carry a number of hallmark mutations of the Omicron variant.
The tests are ongoing to confirm the results against all of the Omicron mutations with an update expected by year-end, it added on Thursday.
In October, Australia's federal government said it received 15,000 doses of sotrovimab.
The national stockpile of the drug, administered by intravenous infusion within five days of patients developing symptoms, was expected to exceed 30,000 doses this year.
It has been shown to reduce hospitalisation or death in patients with mild or moderate infections and who are at high risk of severe illness.
Separately, Britain's drug regulator on Thursday approved sotrovimab for people with mild to moderate COVID-19 who are at high risk of developing severe disease.
Get the latest news from thewest.com.au in your inbox.
Sign up for our emails